Artiva Biotherapeutics, Company Insiders
| ARTV Stock | 10.40 0.22 2.07% |
Artiva Biotherapeutics,'s insiders are aggressively buying. The analysis of the overall insider sentiment regarding Artiva Biotherapeutics, Common suggests that vertually all insiders are extremely bullish. Artiva Biotherapeutics, employs about 82 people. The company is managed by 11 executives with a total tenure of roughly 192 years, averaging almost 17.0 years of service per executive, having 7.45 employees per reported executive.
Artiva Biotherapeutics,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-07-22 | Yong-Jun Huh | Acquired 2083332 @ 12 | View |
Monitoring Artiva Biotherapeutics,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Artiva |
Artiva Biotherapeutics, Management Team Effectiveness
Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.35 in 2024. At this time, Artiva Biotherapeutics,'s Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1.1 M in 2024, whereas Other Assets are likely to drop 4,000 in 2024. Artiva Biotherapeutics,'s management efficiency ratios could be used to measure how well Artiva Biotherapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to climb to about 12.4 M in 2024
Artiva Biotherapeutics, Workforce Comparison
Artiva Biotherapeutics, Common is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 208. Artiva Biotherapeutics, totals roughly 82.0 in number of employees claiming about 39% of equities under Health Care industry.
Artiva Biotherapeutics, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Artiva Biotherapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Artiva Biotherapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Artiva Biotherapeutics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Artiva Biotherapeutics, Notable Stakeholders
An Artiva Biotherapeutics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Artiva Biotherapeutics, often face trade-offs trying to please all of them. Artiva Biotherapeutics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Artiva Biotherapeutics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Flynn | CoFounder Advisor | Profile | |
| Fred MD | CEO President | Profile | |
| Neha Krishnamohan | CFO Development | Profile | |
| JD Esq | COO, VP | Profile | |
| David Moriarty | Senior Operations | Profile | |
| Christopher Horan | Chief Officer | Profile | |
| Thorsten MD | Chief Officer | Profile | |
| Eugene Helsel | Senior Affairs | Profile | |
| Javier MD | Senior Affairs | Profile | |
| C PharmD | Senior Operations | Profile | |
| Heather Raymon | Senior Development | Profile |
About Artiva Biotherapeutics, Management Performance
The success or failure of an entity such as Artiva Biotherapeutics, often depends on how effective the management is. Artiva Biotherapeutics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Artiva management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Artiva management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | 0.17 | 0.16 |
Please note, the imprecision that can be found in Artiva Biotherapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Artiva Biotherapeutics, Common. Check Artiva Biotherapeutics,'s Beneish M Score to see the likelihood of Artiva Biotherapeutics,'s management manipulating its earnings.
Artiva Biotherapeutics, Workforce Analysis
Traditionally, organizations such as Artiva Biotherapeutics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Artiva Biotherapeutics, within its industry.Artiva Biotherapeutics, Manpower Efficiency
Return on Artiva Biotherapeutics, Manpower
| Revenue Per Employee | 408.4K | |
| Revenue Per Executive | 3M | |
| Net Loss Per Employee | 350.2K | |
| Net Loss Per Executive | 2.6M | |
| Working Capital Per Employee | 824.3K | |
| Working Capital Per Executive | 6.1M |
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.